Eric Johnston, chief equity and macro strategist at Cantor Fitzgerald, said he believes stocks are in for a tactical ...

We are entering the buy zone for the momentum factor (BATS:MTUM), (SPMO), according to Eric Johnston, chief equity and macro ...

Leidos Holdings, Inc. (NYSE:LDOS – Free Report) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Leidos in a research note issued on Tuesday ...

Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for CACI International’s current full-year earnings is $23.94 per share. Get CACI International alerts: ...

NVIDIA (NASDAQ:NVDA – Get Free Report)‘s stock had its “overweight” rating reissued by research analysts at Cantor Fitzgerald in a research report issued on Thursday,Benzinga reports.

Years of Experience is the number of years an individual is registered as an investment advisor only, rather than combined years of experience as either an investment advisor or broker.

Domo, Inc. (NASDAQ:DOMO – Free Report) – Equities research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Domo in a research note issued on Tuesday, February 25th.

Cantor Fitzgerald also issued estimates for SoundHound AI’s FY2025 earnings at ($0.21) EPS. Get SoundHound AI alerts: A number of other research analysts have also issued reports on SOUN.

Booz Allen Hamilton Holding Co. (NYSE:BAH – Free Report) – Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Booz Allen Hamilton in a report released on Tuesday ...

Cantor Fitzgerald analyst C. Duncan now anticipates that the biopharmaceutical company will post earnings per share of ($0.51) for the year, down from their prior forecast of ($0.25).

Shares of NASDAQ ASTS opened at $26.08 on Tuesday. The company has a market capitalization of $7.56 billion, a PE ratio of -12.30 and a beta of 1.62. The company has a debt-to-equity ratio of 0.31 ...

Fintel reports that on February 26, 2025, Cantor Fitzgerald downgraded their outlook for Jazz Pharmaceuticals (NasdaqGS:JAZZ) from Overweight to Neutral. Analyst Price Forecast Suggests 30.34% ...